PIPELINE

Our programs 

The Volastra pipeline has multiple programs targeting the unique biology of chromosomally unstable cancer cells. Complementing these programs are our innovative biomarker approaches designed to pair each therapy with the patients who will benefit the most.

Program

Therapeutic Approach

Discovery

Lead Optimization

IND Enabling

Phase 1

PARTNERS

Discovery

Lead Optimization

IND Enabling

Phase 1

Synthetic Lethal

Sovilnesib KIF18A inhibitor

Therapeutic Approach: Synthetic Lethal

Sovilnesib (previously AMG650) is a differentiated oral small molecule KIF18A inhibitor being developed in advanced solid tumors. It recently completed a Phase 1 clinical trial and a Phase 1b trial was initiated in early 2024 (NCT06084416). Sovilnesib has received fast track designation in platinum-resistant high grade serous ovarian cancer.

LEARN MORE

Discovery

Lead Optimization

IND Enabling

Phase 1

Synthetic Lethal

VLS-1488 KIF18A inhibitor

Therapeutic Approach: Synthetic Lethal

VLS-1488 is a differentiated oral small molecule KIF18A inhibitor currently being studied in a Phase 1 clinical trial (NCT05902988) for advanced solid tumors known to have high levels of chromosomal instability.

LEARN MORE

Discovery

Lead Optimization

IND Enabling

Phase 1

Synthetic Lethal

Non-disclosed Targets

Therapeutic Approach: Synthetic Lethal

Bristol Myers logo
Partners:

Together with Bristol Myers Squibb, Volastra is advancing chromosomal instability-specific synthetic lethal efforts against 2 undisclosed targets.

LEARN MORE

Discovery

Lead Optimization

IND Enabling

Phase 1

Immune Activation

New Target Discovery

Therapeutic Approach: Immune Activation

Volastra’s novel approach to Immuno-Oncology is focused on tumor cell-intrinsic Immunoevasion. We are advancing an early pipeline of targets that focus on different ways to re-invigorate anti-tumor immunity, turning chromosomal instability into a driver of immune activation.

LEARN MORE